Xilio Therapeutics IncNASDAQ:XLO
- LAST PRICE3.5700
- TODAY'S CHANGE (%)0.0700 (2.0000%)
- Bid / Lots3.0500/ 1
- Ask / Lots4.8000/ 7
- Open / Previous Close3.5000 / 3.5000
- Day Range
- 52 Week Range
- Volume24,780
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XLO |
|---|---|---|
| 09:32 ET | 331 | 3.5 |
| 09:42 ET | 5100 | 3.49 |
| 09:44 ET | 652 | 3.6 |
| 09:53 ET | 100 | 3.56 |
| 10:26 ET | 280 | 3.6188 |
| 10:27 ET | 150 | 3.61 |
| 10:44 ET | 300 | 3.5701 |
| 10:47 ET | 1300 | 3.65 |
| 10:49 ET | 100 | 3.635 |
| 10:51 ET | 200 | 3.645 |
| 10:58 ET | 700 | 3.67 |
| 11:02 ET | 200 | 3.77 |
| 11:07 ET | 100 | 3.71 |
| 11:09 ET | 275 | 3.71 |
| 11:12 ET | 400 | 3.75 |
| 11:14 ET | 100 | 3.71 |
| 11:23 ET | 3000 | 3.72 |
| 11:52 ET | 2702 | 3.71 |
| 12:15 ET | 3200 | 3.6384 |
| 12:19 ET | 1900 | 3.61 |
| 12:21 ET | 400 | 3.6 |
| 12:37 ET | 100 | 3.62 |
| 12:39 ET | 300 | 3.61 |
| 12:44 ET | 100 | 3.62 |
| 12:50 ET | 100 | 3.62 |
| 12:57 ET | 111 | 3.6115 |
| 01:26 ET | 100 | 3.62 |
| 01:36 ET | 300 | 3.63 |
| 02:02 ET | 100 | 3.63 |
| 02:54 ET | 200 | 3.615 |
| 03:57 ET | 100 | 3.6 |
| 04:00 ET | 100 | 3.57 |
Feb 2, 2023
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day, from 7:30AM ET on Thursday Feb 02, 2023 by GlobeNewswire
7:30AM ET on Thursday Feb 02, 2023 by GlobeNewswire
Jan 27, 2023
--Morgan Stanley Adjusts Price Target on Xilio Therapeutics to $10 From $20, Maintains Overweight Rating, from 11:54AM ET on Friday Jan 27, 2023 by MT Newswires
11:54AM ET on Friday Jan 27, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xilio Therapeutics Inc | 96.2M | -1.1x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 94.9M | -3.6x | --- |
Achieve Life Sciences Inc | 93.1M | -1.3x | --- |
MyMD Pharmaceuticals Inc | 99.5M | -5.7x | --- |
Evelo Biosciences Inc | 99.7M | -0.5x | --- |
NuCana PLC | 84.6M | -2.3x | --- |
Company Information
Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.
Contact Information
- Headquarters
- 828 Winter Street, Suite 300WALTHAM, MA, United States 02451
- Phone
- 617-430-4680
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Paul Clancy
- Non-Executive Independent Chairman of the Board
- Yuan Xu
- President, Chief Executive Officer, Director
- Rene Russo
- President
- Martin Huber
- Chief Operating Officer
- Joseph Farmer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $96.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.14 |
Book Value | $6.78 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
